Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Want to see AKBA full AI Analyst Report?
AKBA Stock Chart & Stats
$1.40
$0.30(14.49%)
At close: 4:00 PM EST
$1.40
$0.30(14.49%)
Day’s Range― - ―
52-Week Range$0.82 - $4.08
Previous CloseN/A
Volume5.66M
Average Volume (3M)6.39M
Market Cap
$305.81M
Enterprise Value$123.47M
Total Cash (Recent Filing)$162.64M
Total Debt (Recent Filing)$12.49M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Jul 30, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding268,258,240
10 Day Avg. Volume7,605,801
30 Day Avg. Volume6,393,504
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)12.70
Price to Sales (P/S)1.75
P/FCF Ratio6.09
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue0.53
Enterprise Value/Gross Profit0.66
Enterprise Value/Ebitda-21.44
Forecast
1Y Price Target
$4.67Price Target Upside233.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$217.59M
Bulls Say, Bears Say
Bulls Say
Vafseo Commercial MomentumSustained quarter-over-quarter and year-over-year Vafseo growth with expanding prescriber count and strong first-refill adherence indicates durable product adoption in dialysis settings. Broader observed-dosing uptake reduces launch risk and underpins scalable recurring revenue over the next 2–6 months.
Improved Cash GenerationA multi-quarter positive free cash flow profile signals that operations are converting revenue into cash, materially lowering near-term financing needs. This stronger cash conversion supports ongoing R&D, commercial expansion, and gives management flexibility to fund planned trials and commercialization without immediate capital raises.
High Gross Margins And Operating ProfitabilityVery high gross margins demonstrate favorable product economics and scalability of sales; positive EBIT reflects improving cost structure. Together these durable margin characteristics provide room to reinvest in pipeline and commercialization while moving the business toward sustained profitability as revenues scale.
Bears Say
Auryxia Generic ErosionPermanent generic entry into Auryxia materially reduces a legacy revenue stream, shrinking predictable cash flow and increasing dependency on Vafseo and pipeline launches. This structural revenue loss forces reallocation of commercial resources and raises the bar for new product uptake to sustain corporate cash flow.
Net Loss, Inventory Charges And Rising CostsInventory obsolescence and higher COGS tied to legacy-product disruptions create durable margin volatility and signal execution risk in supply/forecasting. Combined with a return to net loss, these structural cost shocks erode cash buffers and make sustained profitability more contingent on successful commercialization and pipeline delivery.
Concentration And Enrollment/Adoption RiskCommercial and clinical progress hinges on large dialysis-provider adoption and competitive trial enrollment. Slower observed-dosing rollout at DaVita or crowded FSGS recruitment would delay revenue scaling and trial readouts, extending timelines for realizing the pipeline's value and increasing execution risk over the medium term.
Akebia Therapeutics News
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.82 and its highest was $4.08 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is $305.81M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 32 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on May 07, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.028 by -$0.002.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.04.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 268,258,240 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.028. Following the earnings report the stock price went down -20.27%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in AKBA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (233.33% Upside)
$4.67 (233.33% Upside)
Blogger Sentiment
Bullish
AKBA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 25.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.51%
12-Months-Change
Fundamentals
Return on Equity
-62.72%
Trailing 12-Months
Asset Growth
16.87%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
AKBA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong commercial momentum for Vafseo (32% revenue growth, ~60% patient growth quarter-over-quarter, higher prescriber engagement and improved adherence under observed dosing) and meaningful pipeline progress with supportive clinical data and upcoming readouts. However, legacy product Auryxia faces notable generic-driven revenue decline (≈-17%), the company swung to a net loss in the quarter, experienced sizable inventory write-downs and higher operating expenses, and cash declined q/q. While the launch and clinical developments are encouraging and provide a clear growth narrative, the near-term financial headwinds and competitive/enrollment risks temper the outlook.View all AKBA earnings summariesAKBA Stock 12 Month Forecast
Average Price Target
$4.67
▲(233.33% Upside)
Technical Analysis
Oruka Therapeutics
―
Theravance Biopharma
―
Vir Biotechnology
―
ProKidney
―
ArriVent BioPharma, Inc.
―
Ownership Overview
2.87% Insiders
8.42% Mutual Funds
2.73% Other Institutional Investors
75.58% Public Companies and
Individual Investors